China clears world's first everyday brain implant for paralysis

The News

China has cleared the world's first invasive brain-computer interface for use beyond the confines of a clinical trial. The country's National Medical Products Administration granted approval to NEO, a coin-sized implant developed by Shanghai startup Neuracle Technology alongside researchers at Tsinghua University in Beijing.

Unlike rival systems, NEO does not push electrodes into brain tissue. Its eight sensors rest on the dura mater, the protective membrane surrounding the brain, while a unit fixed to the skull relays signals to a computer. The device is approved for patients aged 18 to 60 who have limb paralysis from spinal cord injuries but retain some arm function.

The headline case is Dong Hui, a 39-year-old from Henan province who was paralysed in a car accident. He received the implant in November 2024 and has since regained the ability to write and grasp objects, helped by daily two-and-a-half hour sessions with a soft robotic glove. "I couldn't believe I was able to write again," he said.

Why It Matters

The approval marks a turning point in a field that has been stuck in the trial phase for years. Neuralink, the best-known name in the sector, implanted its first human patient only in January 2024, and its N1 chip, which threads electrodes directly into the cortex, remains an investigational device. NEO's gentler placement on the dura is a deliberate bet that a less invasive design can clear regulators faster and reach more patients sooner.

Speed is the real story. Researcher Avinash Singh has noted that China's pathway moved in a fraction of the time the US Food and Drug Administration typically takes, where comparable clearance can run to several years. That regulatory tempo is already drawing a pipeline behind NEO. Beinao-1, from the Chinese Institute for Brain Research and NeuCyber NeuroTech, is expected to win approval by 2028, while Cambridge-based Axoft is running its own brain-interface trials with patients in Shanghai. The centre of gravity in neurotech commercialisation is tilting east.

Indian Angle

For India, the lesson is less about silicon and more about process. The country carries one of the world's largest burdens of spinal cord injury, much of it from road accidents, yet has no domestic invasive brain-interface programme close to market. Neural research clusters do exist, from biomedical groups at the IITs to clinical neuroscience work at NIMHANS in Bengaluru, but translating laboratory prototypes into approved devices is where India repeatedly stalls.

The regulatory question is now urgent. India's Central Drugs Standard Control Organisation classifies implantable neural devices among its highest-risk categories, and there is no expedited route comparable to the one Neuracle used. If Chinese and American devices arrive first as imports, Indian patients face the familiar problem of dollar-denominated pricing on technology that domestic players could have built more cheaply for a rupee market.

There is also a data dimension that regulators have barely touched. Brain signals are arguably the most sensitive personal data imaginable, and it is unclear how the Digital Personal Data Protection Act would treat a continuous neural feed. India has time to write those rules before the devices land. China's approval is the signal that the clock has started.

FAQ

What exactly did China approve?

The National Medical Products Administration cleared NEO, an implant from Neuracle Technology and Tsinghua University, for routine clinical use. It is the first invasive brain-computer interface anywhere to move past the trial stage, and is indicated for adults aged 18 to 60 with paralysis from spinal cord injuries.

How is NEO different from Neuralink?

NEO is markedly less invasive. Its eight sensors sit on the dura mater rather than penetrating the cortex, as Neuralink's N1 chip does. The trade-off is a potentially weaker signal in exchange for lower surgical risk, which may help explain why it reached approval ahead of more aggressive designs.

What does this mean for Indian patients?

Not much in the short term. India has no comparable device or expedited approval route, so any rollout would likely come through costly imports priced in dollars, and the Central Drugs Standard Control Organisation would still need to assess them. Domestic neurotech remains years behind on translation.

Where can I read the original announcement?

The detailed reporting on NEO's approval, the patient cases and the wider Chinese pipeline was published by MIT Technology Review. The source link appears in the attribution below.

This story was reported by MIT Technology Review. Read the full original coverage at MIT Technology Review.